Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 7SL, cytoplasmic 292, pseudogene (RN7SL292P) is a human **pseudogene** that is part of a large family of non-coding RNAs derived from the 7SL RNA gene, which encodes the RNA component of the **signal recognition particle (SRP)** complex[1][3][6]. The functional 7SL RNA is essential for directing newly synthesized proteins to the endoplasmic reticulum by pausing translation and targeting the ribosome-protein complex to the membrane, but RN7SL292P itself does **not encode any functional protein or RNA product** and is considered a "dead" genetic element[5][7][8]. Instead, like many pseudogenes, it likely arose from a process in which a functional RNA gene was reverse transcribed and reinserted into the genome, resulting in a sequence that no longer produces a functional product[7][8]. While some 7SL pseudogenes in general have been implicated in gene regulation or disease mechanisms as competitive endogenous RNAs, there is **no current evidence of any biological or disease-related role for RN7SL292P specifically**[4]. RN7SL292P is not a drug target, is not associated with any disease, and has no known impact on patient selection, therapy, or safety.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 292, pseudogene (RN7SL292P).